Clinical trial
The Long COVID Treatment Trial
Active, not recruiting · Phase 2 · 1 countries · Registry ID NCT07128082
What this study is about
The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication. Participants will take the medication (or placebo) they are given and complete study surveys for 12 months. All of the study tasks are done remotely from the comfort of a participants home.
Basic eligibility
Full registry criteria
Treatments and study arms
Tirzepatide
The treatment group will receive the study medication (tirzepatide) for a 12 month period starting with a 2.5mg dose once a week.
Placebo
Participants in the control group will receive a placebo instead of active study medication for a 12 month period.
Primary outcomes
The average difference in Fatigue Severity Scale (minimum score 9, maximum score 63, with higher scores indicating worse fatigue) between treatment and control groups of adults with Long COVID at month 3 or month 12 after study start
Study locations
1 locations were listed when this page was built. The first 40 are shown.